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Age-related loss of the skeletal muscle and its function is known as sarcopenia. Definition and diagnostic criteria for
sarcopenia have been outlined as consensus statements from several study groups, including usual gait speed, grip
strength, and skeletal muscle mass. Whereas underlying mechanisms and pathophysiology of sarcopenia remains to
be clarified, recent studies have suggested that chronic inflammatory status as well as lifestyle-related factors in
older individuals might contribute to the process and progress of sarcopenia.
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Sarcopenia has been recently recognized as an age-related
symptom which is characterized by low muscle mass, low
muscle force, and low physical performance. In this re-
view, we describe the recent progresses regarding the
development of definition and diagnosis of sarcopenia,
as well as its pathophysiology mainly related to age-
related inflammatory processes.Definition and diagnosis of sarcopenia
Recent clinical and studies have suggested the presence
of age-related decline in skeletal muscle mass and muscle
strength from approximately the fifth decade of life, called
sarcopenia [1]. This debilitating process is known to asso-
ciate with frailty, disability [2], and an increased risk of
fall-related fractures [3], leading to higher mortality and
morbidity in the older population [4, 5]. The number of
older population with sarcopenia is expected to increase
all over the world, and it is becoming one of the important
public concerns and interests [6].
Sarcopenia (Greek “sarx” or flesh + “penia” or loss)
was initially proposed by Rosenberg, representing age-
related loss of muscle mass in its original concept [7].
Subsequently, the European Working Group on Sarco-
penia in Older People (EWGSOP) defined sarcopenia in
2010 as a syndrome characterized by progressive and
generalized loss of skeletal muscle mass and strength* Correspondence: suogawa-tky@umin.ac.jp
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ability, poor quality of life, and death [8]. The impact of
sarcopenia on Asian regions including Japan is also es-
timated to be high, and the Asian Working Group for
Sarcopenia (AWGS) agreed to describe sarcopenia as
low muscle mass plus low muscle strength and/or low
physical performance, further recommending its assess-
ment in healthcare settings and in clinical practice [9]
(Fig. 1). Thus, current approaches to the definition of
sarcopenia are based on measurements of muscle mass,
muscle strength, and functional capacity, and each indi-
cator might be considered low when it is less than two
standard deviations (2SD) away from the mean value of
young male and female reference groups. The EWGSOP
has developed a suggested algorithm based on gait speed
measurement as the easiest and most reliable way to begin
sarcopenia case finding or screening in practice.
As for the screening among community-dwelling people
aged 65 years and older, the EWGSOP has developed a
suggested algorithm based on (i) lower skeletal muscle
mass plus (ii) lower gait speed and/or low grip strength
for the diagnosis of sarcopenia [8]. AWGS also recom-
mends using 60 or 65 years as the age for sarcopenia diag-
nosis according to the conditions of each country in Asia
[9]. Operational sarcopenia definition by the International
Working Group for Sarcopenia (IWGS) was targeted
to individuals with functional decline, self-reported
mobility-related difficulties, history of recurrent falls,
recent unintentional body weight loss, post-hospitalization,
and chronic conditions including metabolic diseases andle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Fig. 1 Recommended diagnostic algorithm for sarcopenia by AWGS
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of Health (FNIH) used the data from nine sources of
community-dwelling older population and proposed
the cutoffs based on its analysis [11]. A comparison of
definition/characteristics and cutoff values for sarcope-
nia in EWGSOP, AWGS, and IWGS criteria is shown
in Table 1 [8–10].
It is proposed by the EWGSOP that sarcopenia is con-
sidered primary (or age-related) when no other cause is
evident except aging itself, whereas it is considered sec-
ondary when one or more other causes are evident [8].
In practice, the etiology of sarcopenia is multi-factorial,
and it might not be always possible to identify and
characterize its single cause. EWGSOP also suggests a
conceptual staging as severe sarcopenia, sarcopenia, and
pre-sarcopenia. Severe sarcopenia is the stage when all
three criteria (low muscle mass, low muscle strength, and
low physical performance) are observed. The sarcopenia
stage is defined as low muscle mass, accompanying either
low muscle strength or low physical performance. The
pre-sarcopenia stage is characterized by low muscle mass
without low muscle strength or low physical performance.
Evaluation of these sarcopenia stages might be helpful in
light of setting appropriate recovery goals as well as select-
ing treatments and intervention.Table 1 Comparison of definition/characteristics and cutoff values fo
EWGSOP [8] AWGS [9]
Definition/
characteristics
A syndrome characterized by progressive and
generalized loss of skeletal muscle mass and




SMI 7.26 kg/m2 for men and 5.5 kg/m2 for women
(by DXA). 8.87 kg/m2 for men and 6.42 kg/m2




Walking speed <0.8 m/s <0.8 m/s
Grip force <30 kg for men
<20 kg for women
<26 kg fo
<18 kg foIn terms of epidemiology and prevalence of sarcope-
nia, Baumgartner et al., adopting a skeletal muscle mass
index (SMI) cutoff of −2SDs below the mean of a young
reference group, reported that the prevalence ranged
from 13 to 24 % in persons aged 65 to 70 years old and
was more than 50 % for those who were older than
80 years old [12]. Another study suggested that sarcopenia
was prevalent in 10 % of men and 8 % of women older
than 60 years old and that decrease in skeletal muscle was
independently associated with functional impairment and
disability, especially in older women [13]. The prevalence
of sarcopenia in Japanese elderly men and women, based
on the Asian diagnosis criteria, was 9.6 and 7.7 %, respect-
ively [14]. The number of aged population over 60 years of
age around the world was estimated to be 600 million in
2000 and is expected to rise to 2 billion by 2050. It is also
estimated that sarcopenia will affect over 200 million
people by the period, in contrast to the present estimation
of about 50 million people [15].
Pathophysiology of sarcopenia related to chronic
inflammatory state
It is suggested that significant changes in muscle mass
and its quality are observed during aging process and
that there is a decrease in muscle mass at an annual rater sarcopenia by EWGSOP, AWGS, and IWGS criteria
IWGS [10]
d decline of skeletal muscle plus
le strength and/or physical
ce
Age-associated loss of skeletal
muscle mass and function
for men and 5.4 kg/m2 for women
7.0 kg/m2 for men and 5.7 kg/m2
n (by BIA)
7.23 kg/m2 for men and 5.67 kg/m2
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muscle strength is supposed to be more significant,
reaching to 1.5 % per year in their sixth decade and to
3 % per year afterwards [17]. In average, age-related de-
creases in knee extensor strength are 20–40 % compared
to that of young adult mean [18], and more significant
losses have been observed for those in their ninth de-
cades [19, 20]. Recent findings suggest that multiple fac-
tors including immobility, malnutrition, low protein
intake, changes in hormones and metabolism, systemic
inflammation, and neuromuscular aging are supposed to
influence age-related sarcopenia [21, 22].
From a histological standpoint, the skeletal muscle
consists of type I and type II fibers. Type II fast fibers
possess a higher glycolytic potential, lower oxidative cap-
acity, and faster response, whereas type I slow fibers are
known as fatigue-resistant due to their characteristics
such as greater density and content of mitochondria, ca-
pillaries, and myoglobin. And sarcopenia is characterized
by the predominant atrophy of type II fibers together
with smaller and fewer mitochondria [23, 24]. Although
molecular and cellular mechanisms underlying sarcopenia
still remain to be clarified, age-related low-grade inflam-
mation has been suggested to be involved as described
below.
In general, aging is associated with a significant rise in
serum levels of inflammatory markers and its related fac-
tors [25]. Franceschi et al. described the state of chronic
low-grade inflammatory state as “inflammaging” based
on the related concept of immunosenescence [26, 27].
Inflammation can be beneficial as an acute, transientFig. 2 Influence of potential factors leading to age-related inflammatory primmune response to harmful conditions including tis-
sue injury or pathogen invasion. During aging process,
these acute inflammatory responses may be impaired,
leading to increased susceptibility to infection. Inflam-
maging is characterized as low-grade, chronic, systemic
inflammation in aging in the absence of infection, which
results in responses that lead to tissue degeneration.
Inflammaging is also suggested to be related to various
age-related diseases represented by atherosclerosis, de-
mentia, type 2 diabetes and osteoporosis and is a highly
significant risk factor for both morbidity and mortality in
the elderly people [26, 28] (Fig. 2). Inflammaging is sup-
posed to be a consequence of a reduced immune response
or lifetime exposure to antigenic stimuli [29, 30], leading
to the production of reactive oxygen species and tissue
damage with the release of cytokines mediated by innate
and acquired immune system [31]. In practice, inflam-
maging is accompanied by age-related decline in the
number of T and B cells together with an increase of
natural killer cells [32], and tumor necrosis factor-α
(TNF-α), interleukin-6 (IL-6), interleukin-1 (IL-1), and
C-reactive protein (CRP) are mainly involved in this
process [27, 33, 34]. These cytokines are suggested to lead
to a predisposition to age-related sarcopenia subsequently
through the activation of the ubiquitine-protease system
[35, 36]. And this altered activation of cellular signaling
pathway is considered to promote the inflammatory state
regardless of tissue damage or antigenic exposure, further
contributing to one of the pathogenetic bases underlying
sarcopenia [37–39]. It is also suggested that cytokines may
antagonize the anabolic effect mediated by insulin growthocesses
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which limit IGF-I availability [40, 41]. Inflammaging also
contributes to anabolic resistance, which is one of the
main determinants of sarcopenia, implying that synthesis
of skeletal muscle protein in response to physiologic stim-
uli is below the standard of muscle maintenance in the
older population [42].
Possible cytokines involved in age-related
sarcopenia
Recent findings suggest that some inflammatory cytokines
including TNF-α and IL-6 are involved in pathophysiology
of age-related sarcopenia.
TNF-α
Plasma TNF-α concentration preceded a significant de-
cline in muscle strength at 4 years in study subjects aged
85 years [43] and in decline in muscle mass and its
strength at 5 years in subjects aged 70 to 79 years at
baseline [44]. Exposure of myoblasts to TNF-α causes
inhibition of myogenic differentiation through increased
proteolysis of MyoD by the ubiquitin-proteasome path-
way in vitro [45]. TNF-α is also reported to suppress the
Akt/mTOR pathway [41], promoting muscle catabolism,
oxidative stress, and nitric acid production [46, 47]. De-
crease of TNF-α level mediated by muscle training, for ex-
ample, is suggested to cause muscle regeneration [48–50].
IL-6
Some clinical studies including a longitudinal study in
the Netherlands reported that high levels of IL-6 and
CRP are associated with lower physical performance,
muscle strength, and muscle mass [38, 50–58]. In a 6-year
cohort of community-dwelling elderly subjects, elevated
serum concentrations of IL-6 and IL-1RA have been associ-
ated with decline in physical performance [58]. Hospitalized
geriatric patients with inflammation represented signifi-
cantly weaker muscle function, shoulder extension strength,
and a worse fatigue resistance [59]. In a cross-sectional
study carried out in community-dwelling women aged
more than 65 years, serum IL-6 levels were associated with
higher prevalence of frailty [60]. In older women, higher
serum IL-6 levels were adversely associated with recovery
of lower extremity function after hip fracture [61].
In an experimental study, IL-6 transgenic mice re-
vealed decreased skeletal muscle mass, and anti-mouse
IL-6R antibody inhibited the atrophy [62]. Another study
suggested that IL-6 and serum amyloid A produced in
the liver synergistically increased MuRF1 and atrogin-1
expression by inducing SOCS-3 expression and impairing
its downstream insulin/IGF-1 signaling in the skeletal
muscle [63]. On the other hand, IL-6 is a pleiotropic
cytokine, acting both as an inflammatory cytokine and as
a myokine. For example, acute exercise causes skeletalmuscle contraction and promotes IL-6 release into the
systemic circulation, which could be beneficial for muscle
growth [64]. Further studies are needed to elucidate how
IL-6 are involved in the pathogenesis of age-related
sarcopenia.Other cytokines and inflammatory substrates
A recent study suggested that IL-1 blocked differenti-
ation of human myoblasts into myotubes by activating
TGF-β-activated kinase (TAK)-1 in vitro [65] and might
be involved in sarcopenia. In addition, several clinical
studies imply the relationship between serum CRP con-
centration and sarcopenia. For example, high-sensitivity
CRP levels were significantly associated with sarcopenic
obesity in a Korean study [66]. Proinflammatory cytokines,
such as IL-6 and TNF-α, induce the production of CRP in
the liver, and it has not been clarified whether high CRP
level directly affects sarcopenia.Conclusions
Age-related sarcopenia is a phenomenon that results in
significant mortality as well as morbidity in the older
population and is becoming one of the major public
health problems among aging society. Emerging evidences
suggest underlying mechanisms and pathophysiology of
age-related sarcopenia, in which the relationship between
chronic inflammatory state, muscle strength, and muscle
mass seems to possess a pathogenetic basis including the
control of balance between protein synthesis and its catab-
olism. In terms of inflammaging, age-related changes in
cytokines and hormones levels are also suggested to be
important risk factors for muscular impairment. A better
understanding and knowledge of risk factors for sarcope-
nia is important to promote multidimensional approach
based on its pathophysiology, defining molecular targets
for intervention toward successful prevention and treat-
ment in the near future.
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